Literature DB >> 14708601

Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.

David T Woodley1, Gerald G Krueger, Cynthia M Jorgensen, Janet A Fairley, Tom Atha, Yi Huang, Lawrence Chan, Douglas R Keene, Mei Chen.   

Abstract

Type VII collagen is synthesized and secreted by both human keratinocytes and fibroblasts. Although both cell types can secrete type VII collagen, it is thought that keratinocytes account for type VII collagen at the dermal-epidermal junction (DEJ). In this study, we examined if type VII collagen secreted solely by dermal fibroblasts could be transported to the DEJ. We established organotypic, skin-equivalent cultures composed of keratinocytes from patients with recessive dystrophic epidermolysis bullosa (RDEB) and normal dermal fibroblasts. Immuno-labeling of skin equivalent sections with the anti-type VII collagen antibody revealed tight linear staining at the DEJ. RDEB fibroblasts, were gene-corrected to make type VII collagen and used to regenerate human skin on immune-deficient mice. The human skin generated by gene-corrected RDEB fibroblasts or normal human fibroblasts combined with RDEB keratinocytes restored type VII collagen expression at the DEJ in vivo. Further, intradermal injection of normal human or gene-corrected RDEB fibroblasts into mouse skin resulted in the stable expression of human type VII collagen at the mouse DEJ. These data demonstrate that human dermal fibroblasts alone are capable of producing type VII collagen at the DEJ, and it is possible to restore type VII collagen gene expression in RDEB skin in vivo by direct intradermal injection of fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14708601     DOI: 10.1046/j.1523-1747.2003.12571.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  38 in total

1.  Early intra-amniotic gene transfer using lentiviral vector improves skin blistering phenotype in a murine model of Herlitz junctional epidermolysis bullosa.

Authors:  M Endo; P W Zoltick; A Radu; Q Jiang; J Qiujie; C Matsui; P M Marinkovich; J McGrath; K Tamai; J Uitto; A W Flake
Journal:  Gene Ther       Date:  2011-09-22       Impact factor: 5.250

2.  Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa.

Authors:  Jon Cogan; Jacqueline Weinstein; Xinyi Wang; Yingping Hou; Sabrina Martin; Andrew P South; David T Woodley; Mei Chen
Journal:  Mol Ther       Date:  2014-07-23       Impact factor: 11.454

3.  Cellular responses to disruption of the permeability barrier in a three-dimensional organotypic epidermal model.

Authors:  Gati Ajani; Nobuyuki Sato; Judith A Mack; Edward V Maytin
Journal:  Exp Cell Res       Date:  2007-04-24       Impact factor: 3.905

Review 4.  [Orogenital and conjunctival involvement in hereditary and autoimmune blistering diseases].

Authors:  M Laimer; C M Lanschützer; M Emberger; E Nischler; J Stoiber; H Hintner
Journal:  Hautarzt       Date:  2009-11       Impact factor: 0.751

5.  Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.

Authors:  Johannes S Kern; Stefan Loeckermann; Anja Fritsch; Ingrid Hausser; Wera Roth; Thomas M Magin; Claudia Mack; Marcel L Müller; Oliver Paul; Patrick Ruther; Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

Review 6.  Recessive Dystrophic Epidermolysis Bullosa: Advances in the Laboratory Leading to New Therapies.

Authors:  David T Woodley; Mei Chen
Journal:  J Invest Dermatol       Date:  2015-07       Impact factor: 8.551

7.  Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa.

Authors:  Su M Lwin; Farhatullah Syed; Wei-Li Di; Tendai Kadiyirire; Lu Liu; Alyson Guy; Anastasia Petrova; Alya Abdul-Wahab; Fiona Reid; Rachel Phillips; Maria Elstad; Christos Georgiadis; Sophia Aristodemou; Patricia A Lovell; James R McMillan; John Mee; Snaigune Miskinyte; Matthias Titeux; Linda Ozoemena; Rashida Pramanik; Sonia Serrano; Racheal Rowles; Clarisse Maurin; Elizabeth Orrin; Magdalena Martinez-Queipo; Ellie Rashidghamat; Christos Tziotzios; Alexandros Onoufriadis; Mei Chen; Lucas Chan; Farzin Farzaneh; Marcela Del Rio; Jakub Tolar; Johann W Bauer; Fernando Larcher; Michael N Antoniou; Alain Hovnanian; Adrian J Thrasher; Jemima E Mellerio; Waseem Qasim; John A McGrath
Journal:  JCI Insight       Date:  2019-06-06

8.  Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.

Authors:  K Twaroski; C Eide; M J Riddle; L Xia; C J Lees; W Chen; W Mathews; D R Keene; J A McGrath; J Tolar
Journal:  Br J Dermatol       Date:  2019-07-08       Impact factor: 9.302

9.  A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy.

Authors:  Anja Fritsch; Stefan Loeckermann; Johannes S Kern; Attila Braun; Michael R Bösl; Thorsten A Bley; Hauke Schumann; Dominik von Elverfeldt; Dominik Paul; Miriam Erlacher; Dirk Berens von Rautenfeld; Ingrid Hausser; Reinhard Fässler; Leena Bruckner-Tuderman
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 10.  Molecular therapeutics for heritable skin diseases.

Authors:  Jouni Uitto
Journal:  J Invest Dermatol       Date:  2012-11-15       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.